Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Psyence Biomed Announces $2.0 Million Private Placement | Psychedelic Invest

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the

December 23, 2024

New research highlights potential of cytisine for global smoking cessation efforts

A new study published in Addiction has found that cytisine, a low-cost, generic stop-smoking aid that has been used in eastern Europe since the 1960s,

January 2, 2024

Pre-vaccine COVID-19: US study reveals hospitalization rate of 5.7% and fatality rate of 1.7%

Study estimates COVID-19 hospitalization and mortality rates in the US during the pre-vaccination period, revealing significant age and racial disparities in outcomes.

May 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.